6-104744232-TAAC-T
Position:
Variant summary
Our verdict is Benign. Variant got -16 ACMG points: 0P and 16B. BP6_Very_StrongBA1
The NM_020771.4(HACE1):c.2443-5_2443-3del variant causes a splice region, splice polypyrimidine tract, intron change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.161 in 1,575,176 control chromosomes in the GnomAD database, including 24,603 homozygotes. 1/1 splice prediction tools predict no significant impact on normal splicing. Variant has been reported in ClinVar as Benign (★★).
Frequency
Genomes: 𝑓 0.22 ( 4917 hom., cov: 26)
Exomes 𝑓: 0.15 ( 19686 hom. )
Consequence
HACE1
NM_020771.4 splice_region, splice_polypyrimidine_tract, intron
NM_020771.4 splice_region, splice_polypyrimidine_tract, intron
Scores
Not classified
Clinical Significance
Conservation
PhyloP100: 2.25
Genes affected
HACE1 (HGNC:21033): (HECT domain and ankyrin repeat containing E3 ubiquitin protein ligase 1) This gene encodes a HECT domain and ankyrin repeat-containing ubiquitin ligase. The encoded protein is involved in specific tagging of target proteins, leading to their subcellular localization or proteasomal degradation. The protein is a potential tumor suppressor and is involved in the pathophysiology of several tumors, including Wilm's tumor. [provided by RefSeq, Mar 2016]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Benign. Variant got -16 ACMG points.
BP6
Variant 6-104744232-TAAC-T is Benign according to our data. Variant chr6-104744232-TAAC-T is described in ClinVar as [Benign]. Clinvar id is 1599999.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
BA1
GnomAd4 highest subpopulation (AFR) allele frequency at 95% confidence interval = 0.418 is higher than 0.05.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
HACE1 | NM_020771.4 | c.2443-5_2443-3del | splice_region_variant, splice_polypyrimidine_tract_variant, intron_variant | ENST00000262903.9 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
HACE1 | ENST00000262903.9 | c.2443-5_2443-3del | splice_region_variant, splice_polypyrimidine_tract_variant, intron_variant | 1 | NM_020771.4 | P1 |
Frequencies
GnomAD3 genomes AF: 0.224 AC: 34021AN: 151752Hom.: 4900 Cov.: 26
GnomAD3 genomes
AF:
AC:
34021
AN:
151752
Hom.:
Cov.:
26
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.164 AC: 41071AN: 250952Hom.: 4173 AF XY: 0.160 AC XY: 21687AN XY: 135652
GnomAD3 exomes
AF:
AC:
41071
AN:
250952
Hom.:
AF XY:
AC XY:
21687
AN XY:
135652
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.155 AC: 220054AN: 1423308Hom.: 19686 AF XY: 0.155 AC XY: 110098AN XY: 710576
GnomAD4 exome
AF:
AC:
220054
AN:
1423308
Hom.:
AF XY:
AC XY:
110098
AN XY:
710576
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.224 AC: 34077AN: 151868Hom.: 4917 Cov.: 26 AF XY: 0.221 AC XY: 16372AN XY: 74232
GnomAD4 genome
AF:
AC:
34077
AN:
151868
Hom.:
Cov.:
26
AF XY:
AC XY:
16372
AN XY:
74232
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
Asia WGS
AF:
AC:
321
AN:
3470
EpiCase
AF:
EpiControl
AF:
ClinVar
Significance: Benign
Submissions summary: Benign:2
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
not provided Benign:1
Benign, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 31, 2024 | - - |
Spastic paraplegia-severe developmental delay-epilepsy syndrome Benign:1
Benign, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Sep 13, 2021 | - - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at